DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: NNC0113-6856
Drug: Placebo

First Posted Date: 2023-10-06

Last Posted Date: 2025-05-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 170

Registration Number: NCT06069895

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Cagrilintide
Drug: Placebo cagrilintide
Drug: Semaglutide
Drug: Placebo semaglutide

First Posted Date: 2023-10-04

Last Posted Date: 2025-05-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2734

Registration Number: NCT06065540

Locations: 🇬🇷
"Laiko" General Hospital of Athens, Athens, Greece
🇬🇷
General hospital of Athens 'G.Gennimatas', Athens, Greece
🇬🇷
Iatriko Athinon (Athens Medical Canter), Athens, Greece

and more 337 locations

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Phase 2

Completed

Conditions: Obesity
Overweight

Interventions: Drug: NNC0487-0111
Drug: Placebo (NNC0487-0111)

First Posted Date: 2023-10-03

Last Posted Date: 2025-01-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 125

Registration Number: NCT06064006

Locations: 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
🇺🇸
Novo Nordisk INvestigational Site, San Antonio, Texas, United States

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Placebo (NNC0487-0111)
Drug: NNC0487-0111

First Posted Date: 2023-09-22

Last Posted Date: 2025-03-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT06049329

Locations: 🇯🇵
Hakata Clinic, Fukuoka, Japan

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

Phase 3

Completed

Conditions: Overweight
Obesity

Interventions: Drug: Placebo
Drug: Semaglutide

First Posted Date: 2023-09-18

Last Posted Date: 2025-05-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 242

Registration Number: NCT06041217

Locations: 🇨🇳
Beijing Hospital, Beijing, Beijing, China
🇨🇳
Chongqing University Three Gorges Hospital, ChongQing, Chongqing, China
🇨🇳
Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan

and more 17 locations

A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Semaglutide

First Posted Date: 2023-08-18

Last Posted Date: 2024-08-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 121

Registration Number: NCT05996874

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

Phase 3

Completed

Conditions: Obesity or Overweight

Interventions: Drug: Cagrilintide
Drug: Semaglutide
Drug: Placebo Semaglutide
Drug: Placebo Cagrilintide

First Posted Date: 2023-08-18

Last Posted Date: 2025-03-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 300

Registration Number: NCT05996848

Locations: 🇨🇳
Chinese People's Liberation Army General Hospital-Endocrinology, Beijing, Beijing, China
🇨🇳
Chongqing University Three Gorges Hospital, ChongQing, Chongqing, China
🇨🇳
Fujian Medical University Union Hospital-Endocrinology, Fuzhou, Fujian, China

and more 28 locations

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Phase 1

Completed

Conditions: Dyslipidaemia
Healthy Volunteers

Interventions: Drug: NNC0491-6075
Drug: Placebo

First Posted Date: 2023-08-07

Last Posted Date: 2025-05-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 106

Registration Number: NCT05979428

Locations: 🇺🇸
Altasciences Clinical LA, Inc., Cypress, California, United States

A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

Phase 1

Completed

Conditions: Healthy Volunteers
Hepatic Impairment

Interventions: Drug: NNC0194-0499

First Posted Date: 2023-06-26

Last Posted Date: 2025-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 33

Registration Number: NCT05917938

Locations: 🇵🇱
Uniwersyteckie Centrum Kliniczne (UCK), Gdańsk, Poland
🇸🇰
Summit Clinical Research s.r.o., Malacky, Slovakia
🇩🇪
APEX Research, München, Germany

A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

Recruiting

Conditions: Idiopathic Short Stature

Interventions: Other: No treatment is given

First Posted Date: 2023-06-08

Last Posted Date: 2024-10-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 700

Registration Number: NCT05894876

Locations: 🇧🇷
University of Sao Paulo School of Medicine, São Pauloa, Brazil
🇺🇸
Novo Nordisk Investigational Site, Columbia, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy